Relative Bioavailability Study of HRG2010 in Healthy Subjects

Summary

This is a single-center, randomized, open-label, four-period, crossover study. Primary Objective： 1. To evaluate the pharmacokinetic characteristics of healthy subjects after a single oral dose of HRG2010 capsules at dose 1 and dose 2 under fasting conditions, and to compare these with the pharmacokinetic characteristics of Carbidopa/Levodopa Extended-Release Tablets (Sinemet®) and Benserazide/Levodopa Tablets (Madopar®). Secondary Objective 2. To assess safety following administration.

Timeline

Start

2021-09-10

Primary completion

2021-10-07

Completion

2021-10-07

Drugs

Indications